MEDICUD Secures €715M to Transform Incisional Wound Therapy with DRYUM

MEDICUD, the innovative Italian medtech startup making waves in the wound healing sector, has announced a momentous funding round of 715,000,000. This significant investment marks a major milestone in the company’s journey as it aims to revolutionize incisional wound care with its flagship product, DRYUM. DRYUM is a groundbreaking incisional negative pressure wound therapy system that uniquely blends the gold standard of care with unmatched patient comfort. As the only ultraportable mechanical system designed to deliver constant negative pressure throughout the entire treatment process, DRYUM sets a new paradigm for cost-effective and efficient healing in incisional surgery. The infusion of funds will accelerate MEDICUD’s efforts as it moves forward in its clinical phase, currently conducting in-human trials for DRYUM. With the financial support, the company is poised to enhance its research and development initiatives, optimize its production capabilities, and expand its market reach to ensure that this innovative technology becomes the standard of care in reducing severe postoperative complications such as surgical site infections and dehiscence. Moreover, the strategic investment underlines MEDICUD’s commitment to sustainable healthcare solutions, as DRYUM’s eco-friendly design utilizes bio-sourced polymers and deliberately avoids embedded electronics, significantly reducing its environmental footprint. This funding not only reinforces the company’s position as a leader in medical device innovation but also paves the way for transformative advancements in patient care. By driving forward with robust clinical evidence and scalable production, MEDICUD is set to transform incisional wound therapy and improve surgical outcomes globally.